Last edition
News about "CNS stimulant"
Otsuka Receives US FDA Approval for First-in-Class SIMTRIYO
The US Food and Drug Administration (FDA) has approved Otsuka's SIMTRIYO, the first Norepinephrine, Dopamine, Serotonin Reuptake Inhibitor (NDSRI) for treating ADHD in adults and children aged 6 years and older weighing at least 20 kg.
CNS Stimulant | 27/07/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members